Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 10Recurrence 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1Astrocytoma 1Adult Solid Neoplasm 1

Interventions

talimogene laherparepvec 1poly(I).poly(c12,U) 1pasireotide 1liposomal doxorubicin 1Taxes 1Tamoxifen 1Sulindac 1Palliative Care 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Metformin 1Letrozole 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunohistochemistry 1Fluorescent Antibody Technique 1Flow Cytometry 1Fatty Acids, Omega-3 1Doxorubicin 1Docosahexaenoic Acids 1Cyclophosphamide 1Celecoxib 1CTLA-4 Antigen 1Biopsy 1Bexarotene 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Carcinoma In Situ × Introns × Clear all
NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡